Amolyt Pharma logo
VerifiedBiotechnology Research· Founded 2015

Amolyt Pharma

Amolyt Pharma is building on its team’s established expertise to deliver life-changing treatments to patients suffering from rare endocrine and related diseases. Amolyt Pharma’s portfolio includes eneboparatide (AZP-3601), a long-acting PTH1 receptor agonist as a potential treatment for hypoparathyroidism, and AZP-3813, a peptide growth hormone receptor antagonist for the potential treatment of acromegaly. Amolyt Pharma aims to further expand and develop its portfolio by leveraging its global network in the field of endocrinology and with support from a strong syndicate of international investors.

7-day free trial · no credit card

Employees21(11 to 50)Founded year2015Websiteamolytpharma.comLinkedIn profileLinkedIn

Verified contacts

21

available on Kipplo

LinkedIn employees

21

11 to 50 range

Open roles

no listings

Distinct roles

19

indexed titles

Tech stack

1

tools in use

Monthly traffic

59

organic / mo

Sign up free to see all 21 verified contacts at Amolyt Pharma

Free for 7 days · 50 credits · no card · only pay for verified records.

Sign up free

Decision-makers and verified team members

21 contacts with verified email or phone · masked until revealed.

Sign up free →

Top roles at Amolyt Pharma

19 distinct titles indexed · top 10 shown.

  • 2clinical project leader
  • 2é -
  • 1- é - - é
  • 1ass dir preclinical development
  • 1chairman of the board
  • 1chief financial officer
  • 1chief scientific officer
  • 1clinical supply manager
  • 1consultant
  • 1director of quality assurance
  • +9more titles

Sign up to unlock all 21 contacts at Amolyt Pharma

Free for 7 days · 50 credits · no card · only pay for verified records.

Sign up free

Sign up to reveal 21 verified contacts at Amolyt Pharma

7-day trial · no credit card · cancel anytime · only pay for verified records.

Trusted by sales, marketing, and GTM engineering teams.

Amolyt Pharma | Kipplo Discover